Latest On Myles Jack’s Knee Injury

5:48pm: A potential Jack suitor, the Cowboys have placed Jack on their sub board — a distinction for players with medical risks that a team will consider only if they fall to a certain point — according to Charles Robinson of Yahoo.com (on Twitter). At No. 4, Dallas doesn’t have a place for Laremy Tunsil but would be in play for Jalen Ramsey, or possibly Joey Bosa or DeForest Buckner.

Multiple teams also think Jack will require microfracture surgery at some point, Peter King of TheMMQB.com reports (on Twitter). Jadeveon Clowney was the latest high-profile player to undergo that procedure, doing so last year. That operation also caused Travis Kelce to miss his rookie season in 2013.

4:59pm: UCLA linebacker Myles Jack is dealing with a chondral defect in his right knee, according to Albert Breer of NFL.com (Twitter links). It’s unclear whether the defect was caused by Jack’s September knee injury, but he can play with the ailment — the length of his career, however, is still up for debate, per Breer."<strong

As Dr. Jene Bramel of FootballGuys.com explains (all Twitter links), a chondral defect is another term for cartilage loss. The injury is to be expected, according to Bramel, who believes that Jack looked good in his latest workout videos — but it’s apparently incredibly difficult to project how the ailment will affect the longevity of Jack’s career. Many NFL players deal with cartilage loss, per Bramel, and each player handles the injury differently (for example, one player might play through the ailment, another might need microfracture surgery).

As expected, the clarity on Jack’s injury could have an impact on his draft stock, and Breer reports (via Twitter) that clubs outside the top 10 picks are now doing more research on Jack in the hopes that he might slip. Breer adds (link) that it’s simply a matter of opinion as to how Jack’s knee will hold up, and some clubs have indicated that they don’t view the injury as a concern.

Photo courtesy of USA Today Sports Images.

View Comments (2)